Physician profile
Lynn M Wright
NPI 1386930519
$1,045.92
in general payments reported to CMS, 2019-2025
19 companies · $81.89 in 2025
The $81.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $131 · 2021: $192 · 2022: $212 · 2023: $73.99 · 2024: $169 · 2025: $81.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $224.79 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $140.58 | 2022-2025 | Qulipta |
| Glaxosmithkline, LLC. | $111.62 | 2019-2022 | |
| Pfizer INC. | $108.29 | 2019-2021 | |
| Lilly USA, LLC | $63.49 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $56.11 | 2019-2020 | |
| Abbott Laboratories | $53.78 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $50.21 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $34.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.75 | 2021-2022 | |
| Astellas Pharma US INC | $32.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.23 | 2022 | |
| Lundbeck LLC | $22.69 | 2024 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2019 | |
| Celgene Corporation | $16.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $16.14 | 2019 | |
| Merck Sharp & Dohme LLC | $14.83 | 2024 | Gardasil, Gardasil 9 |
| Inspire Medical Systems, INC. | $13.44 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $12.81 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.